BRIEF: Haixi Pharma delays IPO trading debut
Fujian Haixi Pharmaceuticals Co. Ltd. (2637.HK) said on Thursday night that the trading debut for its Hong Kong IPO, originally scheduled for Friday, will be postponed. It blamed the delay on failure to finalize terms, including the final offering price, subscription levels for the international placement, and the Hong Kong public share allotment methodology, and to obtain regulatory approval by the 8 a.m. Friday deadline.
Some brokers began notifying clients of their share allotments as early as Wednesday afternoon, indicating the price had been set at HK$86.40. Trading commenced on the gray market on Thursday over broker platforms. Positions at Futu Securities surged sharply early on, briefly commanding a premium of 131% at HK$200 versus the set price. However, the gains later fell sharply to just over 20%.
Haixi Pharmaceuticals had aimed to raise HK$990 million ($127 million) by selling 11.5 million shares. Its prospectus quoted a price range of HK$69.88 to HK$86.40 per share.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
BRIEF: Sanhua denies massive Tesla order rumors after stock surges
BRIEF: WeRide, Pony AI approved by CSRC to list in Hong Kong
RELATED ARTICLES
-
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK 600276.SHG -
BRIEF: RongTa surges in Hong Kong trading debut
9881.HK
-
BRIEF: CATL jumps in trading debut as Hong Kong’s biggest IPO this year
3750.HK 300750.SHE
-
BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
1276.HK 600276.SHG
-
BRIEF: Auntea Jenny surges in Hong Kong trading debut
2589.HK
-
BRIEF: Zhou Liu Fu rises in Hong Kong trading debut
6168.HK
-
BRIEF: Leads Biolab nearly doubles in Hong Kong trading debut
9887.HK
